501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro

501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro

The newly emerging variants of SARS-CoV-2 from South Africa (B.1.351/501Y.V2) and Brazil (P.1/501Y.V3) have led to a higher infection rate and reinfection of COVID-19 patients. We found that the mutations K417N, E484K, and N501Y within the receptor-binding domains (RBDs) of the virus could confer ~2...

Full description

Bibliographic Details
Main Authors: Haolin Liu, Pengcheng Wei, Qianqian Zhang, Zhongzhou Chen, Katja Aviszus, Walter Downing, Shelley Peterson, Lyndon Reynoso, Gregory P. Downey, Stephen K. Frankel, John Kappler, Philippa Marrack, Gongyi Zhang
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:mAbs
Subjects:
SARS-COV-2
COVID-19
B.1.1.7/501Y.V1
B.1.351/501Y.V2
P.1/501Y.V3
ACE2
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2021.1919285

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2021.1919285

Similar Items